Allogeneic Virus-specific T Cell Lines (VSTs)
Viral Infections After HSCT
About this trial
This is an interventional treatment trial for Viral Infections After HSCT
Eligibility Criteria
Inclusion Criteria:
- Received prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow, single/double cord blood or PBSC
Cells administered as;
- Treatment of persistent or relapsed reactivation or infection
- Early treatment for single or multiple infections with EBV, CMV and/or adenovirus
- Steroids less or equal to 0.5 mg/kg/day prednisone
5)Bilirubin <3x, AST <3x, Serum creatinine <2x upper limit of normal, Hgb >8.0, plts >20 6) Pulse oximetry of > 90% on room air 7) Available VSTs 8) Negative pregnancy test (if female of childbearing potential after reduced intensity conditioning) 9) Patient or parent/guardian capable of providing informed consent.
Exclusion Criteria:
- Received ATG, Campath or other T cell immunosuppressive monoclonal antibodies in the last 28 days.
- Patients with other uncontrolled infections
- Received donor lymphocyte infusion in last 28 days
- Evidence of GVHD > or equal to grade 2
- Active and uncontrolled relapse of malignancy
Sites / Locations
- Childrens National Medical Center
Arms of the Study
Arm 1
Experimental
VSTs against three viruses
Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team. If participants have a partial response (as defined by a 50% fall in viral load) they are eligible to receive up to 4 additional doses from day 28 after the initial infusion and at 2 weekly intervals thereafter.